Innoviva, Inc. INVA
We take great care to ensure that the data presented and summarized in this overview for Innoviva, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INVA
View all-
Black Rock Inc. New York, NY9.63MShares$176 Million0.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT7.28MShares$133 Million39.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.31MShares$115 Million0.0% of portfolio
-
Putnam Investments LLC Boston, MA6.27MShares$115 Million0.14% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.92MShares$89.9 Million0.02% of portfolio
-
Franklin Resources Inc San Mateo, CA4.43MShares$81 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.26MShares$77.9 Million0.12% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.93MShares$53.6 Million0.13% of portfolio
-
State Street Corp Boston, MA2.46MShares$44.9 Million0.0% of portfolio
-
Systematic Financial Management LP Teaneck, NJ2.03MShares$37.1 Million0.93% of portfolio
Latest Institutional Activity in INVA
Top Purchases
Top Sells
About INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Insider Transactions at INVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 14
2025
|
Pavel Raifeld |
BUY
Grant, award, or other acquisition
|
Direct |
37,377
+42.79%
|
$635,409
$17.39 P/Share
|
|
Mar 06
2025
|
Alexander J Denner |
SELL
Open market or private sale
|
Indirect |
1,196,746
-17.46%
|
$20,344,682
$17.52 P/Share
|
|
Mar 05
2025
|
Alexander J Denner |
SELL
Open market or private sale
|
Indirect |
270,374
-3.79%
|
$4,596,358
$17.63 P/Share
|
|
Mar 04
2025
|
Alexander J Denner |
SELL
Open market or private sale
|
Indirect |
151,175
-2.08%
|
$2,569,975
$17.63 P/Share
|
|
Feb 24
2025
|
Stephen Basso Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,569
+32.06%
|
$190,242
$18.08 P/Share
|
|
Feb 24
2025
|
Marianne Zhen Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,938
+14.83%
|
$160,884
$18.08 P/Share
|
|
Feb 20
2025
|
Stephen Basso Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,106
-8.55%
|
$19,908
$18.07 P/Share
|
|
Feb 20
2025
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,565
-5.71%
|
$46,170
$18.07 P/Share
|
|
Nov 20
2024
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
976
-2.13%
|
$18,544
$19.15 P/Share
|
|
Nov 15
2024
|
Stephen Basso Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
843
+6.12%
|
-
|
|
Nov 15
2024
|
Marianne Zhen Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.65%
|
-
|
|
Aug 20
2024
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
975
-2.09%
|
$17,550
$18.49 P/Share
|
|
Jun 17
2024
|
Derek A Small Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+37.53%
|
-
|
|
Jun 17
2024
|
Sapna Srivastava Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+24.0%
|
-
|
|
Jun 17
2024
|
Jules Haimovitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+9.62%
|
-
|
|
Jun 17
2024
|
Kostas D Odysseas Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+10.2%
|
-
|
|
Jun 17
2024
|
Sarah J. Schlesinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+10.5%
|
-
|
|
Jun 17
2024
|
Mark Di Paolo Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+10.5%
|
-
|
|
May 20
2024
|
Matthew Ronsheim |
SELL
Payment of exercise price or tax liability
|
Direct |
268
-0.66%
|
$4,288
$16.13 P/Share
|
|
May 20
2024
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
976
-2.05%
|
$15,616
$16.13 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 142K shares |
|---|
| Payment of exercise price or tax liability | 6.87K shares |
|---|---|
| Open market or private sale | 1.62M shares |